Study: Alzheimer's imaging can ID disease decades before harm

According to a study by Australian researchers, it takes about 20 years for beta amyloid deposits, biomarkers for Alzheimer's, to lead to full-fledged dementia, meaning that if build-ups can be identified early through brain scans, physicians have a sizable window for treating the disease. This could be good news for the likes of GE Healthcare ($GE) and Navidea Biopharmaceuticals ($NAVB), which are both developing imaging agents designed to ferret out beta amyloid in the brain, but, to date, drug developers have struggled mightily to craft treatments that can reverse the disease's progress. Report

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.